



Human Anti-Cemiplimab monoclonal antibody, clone AbD41949ia (CABT-ZB1157)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Cemiplimab
Target	Cemiplimab
Immunogen	Cemiplimab
Isotype	IgG1, λ
Source/Host	Human
Species Reactivity	N/A
Clone	AbD41949ia
Affinity Constant	The monovalent intrinsic affinity of AbD41949ia was measured as $K_D = 6$ nM by real time, label free molecular interaction analysis on immobilized cemiplimab.
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in ADA bridging ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	Lot specific
Size	100 μ g

Buffer	PBS
Preservative	0.01% Thiomersal
Storage	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Ship	Wet ice

BACKGROUND

Introduction	Cemiplimab (Libtayo) is a fully human IgG4/kappa antibody. It has been approved for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) and for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression. Cemiplimab acts as a checkpoint inhibitor by binding to the PD-1 receptor and blocking its interaction with PD-L1 and PD-L2 ligands.
Keywords	Cemiplimab; Libtayo